Man unsure of the safety of his medicine

Breaking news and expert analysis on legal and compliance issues

[Back To Home][Back To Archives]

From Products Liability Law Daily, March 11, 2015

Johnson & Johnson subsidiary pleads guilty for adulterated over-the-counter infant medications

By Bryant Storm, J.D.

McNeil-PPC Inc., a Johnson & Johnson subsidiary, pleaded guilty to one count of delivering for introduction into interstate commerce adulterated infants’ and children’s over-the-counter (OTC) liquid medicines, according to a Department of Justice (DOJ) press release. As part of the plea agreement to resolve the criminal matter, McNeil agreed to pay a $20 million fine and forfeit an additional $5 million.

Current Good Manufacturing Practices. According to the criminal charge, the infants’ and children’s liquid medicines were adulterated because they were not manufactured, processed, packed or held according to current Good Manufacturing Practices (CGMPs), in violation of the federal Food, Drug, and Cosmetic Act (FDC Act) (21 U.S.C. § 301). Specifically the charges alleged that as a result of McNeil’s production process for its infant and child OTC liquid medicines, metal pistons and cylinders had direct contact with liquid in the OTC medicines, in contravention of CGMP standards. The violations were discovered through McNeil’s own findings, a consumer complaint, and an FDA investigation, all of which identified foreign materials in the medication. The foreign materials were identified as “including nickel/chromium-rich inclusions, which were not intended ingredients in this OTC liquid drug.” According to the charges, there were several incidents in which McNeil identified metal particles in bottles of Infants’ Tylenol®, but failed to develop a Corrective Action Preventive Action (CAPA) plan to correct the problem.

Injunction. According to the plea agreement, in addition to the monetary penalties, McNeil will continue to be subject to a permanent injunction that was established in 2011 when McNeil was under criminal investigation. The injunction serves to ensure that McNeil does not operate facilities unless and until they are brought into compliance with CGMP standards. The provisions of the plea agreement are designed to deter McNeil from future noncompliance and preserve the quality of the medications that the manufacturer produces. Speaking of the seriousness of the offense, Acting Assistant Attorney General Mizer said that the DOJ “will continue to be aggressive in pursuing and punishing companies such as McNeil that disregard a process designed to assure quality medicines, especially OTC drugs for infants and children.”

Companies: McNeil-PPC Inc.; Johnson & Johnson

MainStory: TopStory DrugsNews ChildrensProductsNews BabyProductsNews SettlementAgreementsNews

Products Liability Law Daily

Introducing Wolters Kluwer Products Liability Law Daily — a daily reporting service created by attorneys, for attorneys — providing same-day coverage of breaking news, court decisions, legislation, and regulatory activity.


A complete daily report of the news that affects your world

  • View full summaries of federal and state court decisions.
  • Access full text of legislative and regulatory developments.
  • Customize your daily email by topic and/or jurisdiction.
  • Search archives for stories of interest.

Not just news — the right news

  • Get expert analysis written by subject matter specialists—created by attorneys for attorneys.
  • Track law firms and organizations in the headlines with our new “Who’s in the News” feature.
  • Promote your firm with our new reprint policy.

24/7 access for a 24/7 world

  • Forward information with special copyright permissions, encouraging collaboration between counsel and colleagues.
  • Save time with mobile apps for your BlackBerry, iPhone, iPad, Android, or Kindle.
  • Access all links from any mobile device without being prompted for user name and password.